CDC25B
MOLECULAR TARGETcell division cycle 25B
CDC25B (cell division cycle 25B) is targeted by 9 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).
Compounds Targeting CDC25B
Ranked by bioassay confidence score (PubChem active assay count × evidence quality).
| # | Compound | Confidence | Active Assays |
|---|---|---|---|
| 1 | Vitamin K 3 | 1.39 | 3 |
| 2 | plumbagin [Supplementary Concept] | 0.69 | 1 |
| 3 | Anthraquinones Compounds based on ANTHRACENES which contain two KETONES in | 0.69 | 1 |
| 4 | Aurintricarboxylic Acid | 0.69 | 1 |
| 5 | juglone hydroxylase [Supplementary Concept] catalyzes | 0.69 | 1 |
| 6 | Methylergonovine | 0.69 | 1 |
| 7 | Nadolol | 0.69 | 1 |
| 8 | 1-(5,8-dihydro-1,4-dihydroxy-5,8-dioxo-2-naphthyl)-4-methylpent-3-en-1-yl cinnamate [Supplementary Concept] | 0.69 | 1 |
| 9 | Oleanolic Acid | 0.69 | 1 |
About CDC25B as a Drug Target
CDC25B (cell division cycle 25B) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 9 compounds with documented CDC25B interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.
CDC25B inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.